Apitegromab (Isembyld)

Structure: Apitegromab is a fully human IgG4 monoclonal antibody, not a peptide. Myostatin is produced as an inactive precursor (promyostatin), cleaved to a latent form, then activated by a tolloid protease. Apitegromab binds the two inactive precursor forms and blocks that final activation step. It does not bind mature myostatin.

Why that selectivity matters: ACE-031 is a soluble receptor decoy that also mops up activin A, GDF-11 and several bone morphogenetic proteins, and follistatin binds myostatin and activin A. Both are blunt by comparison. Apitegromab acts only on the myostatin precursors, which is why it is the first drug in this class to reach approval rather than being abandoned.

Approved use (what the label actually says):

• Spinal muscular atrophy, adults and children aged 2 and over, only as an add-on for patients already receiving nusinersen or risdiplam
• 10mg/kg intravenously every 4 weeks, infused over roughly 60 to 120 minutes in a clinic or infusion centre
• There is no subcutaneous form, no self-administered form, and no approved indication for muscle growth, weight loss or athletic use
• Reported net cost is around 310,000 US dollars per year for a typical patient

There is no bodybuilding dosing protocol, and this entry will not invent one. No trial has measured hypertrophy in a healthy adult. The Phase 1 study in healthy volunteers measured safety, pharmacokinetics and target engagement only; it had no muscle mass, muscle volume or strength endpoint.

What the human evidence shows:

• SAPPHIRE (Phase 3, SMA): 188 non-ambulatory patients aged 2 to 21. At the approved 10mg/kg dose the Hammersmith motor scale improved 2.2 points against placebo, on a scale running to 66. Responders gaining at least 3 points were 34.2 percent against 13.5 percent. The label describes the p-values as nominal.
• EMBRAZE (Phase 2, adults on tirzepatide): 102 adults with overweight or obesity. Lean mass loss was 1.6kg against 3.5kg on placebo, a 1.9kg difference, with similar total weight loss. Lean tissue made up 14.6 percent of weight lost against 30.2 percent. Exploratory handheld dynamometry and chair sit-to-stand testing showed no notable difference from placebo, so the retained tissue did not translate into measurable function over 24 weeks.

Key Notes:

• The class has a consistent pattern worth knowing: bimagrumab and taldefgrobep both increased muscle volume in healthy volunteers without improving strength, and ACE-031 raised lean mass before development was stopped on safety grounds. Size and function come apart repeatedly in these drugs.
• Fractures are the headline safety signal. In the pivotal trial, fractures occurred in 9 percent at 10mg/kg, 6 percent at 20mg/kg and 2 percent on placebo, including three femur fractures, some with no clear precipitating event. Most affected patients already had low bone density, prior fractures or contractures, so the rate cannot be read straight across to an adult with normal bone. Rat studies showed femoral head and neck changes with no no-effect dose identified.
• Animal data indicate possible fetal harm and possible effects on reproductive function.
• The European application was withdrawn in August 2026 over a fill-finish manufacturing site inspection, not for safety or efficacy. There is no public information about a TGA submission in Australia as of November 2026.
• Material sold online as "research grade apitegromab" is laboratory catalogue reagent, not sterile injectable clinical product, and carries all the usual purity and contamination problems.
• If lean mass loss on a GLP-1 is the concern, resistance training, adequate protein, a slower rate of loss and actual body composition measurement are the interventions with evidence behind them.
• Monitor if ever used clinically: bone markers (ALP, calcium, phosphate, PTH, vitamin D), creatine kinase, and DXA for bone density, since bloodwork alone will not show bone loss.
• Further reading: Will apitegromab build muscle in healthy lifters?

References:

• Crawford, T. O., Servais, L., Mercuri, E., et al. (2025). Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurology, 24(9), 727-739. DOI: 10.1016/S1474-4422(25)00225-X
• Pratley, R. E., Denham, D. S., Trivedi, R., et al. (2026). Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Medicine, 32(7), 2673-2678. DOI: 10.1038/s41591-026-04440-4
• Pirruccello-Straub, M., Jackson, J., Wawersik, S., et al. (2018). Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Scientific Reports, 8(1), 2292. DOI: 10.1038/s41598-018-20524-9
• Barrett, D., Bilic, S., Chyung, Y., et al. (2021). A randomized phase 1 safety, pharmacokinetic and pharmacodynamic study of the novel myostatin inhibitor apitegromab (SRK-015). Advances in Therapy, 38(6), 3203-3222. DOI: 10.1007/s12325-021-01757-z
• Crawford, T. O., Darras, B. T., Day, J. W., et al. (2024). Safety and efficacy of apitegromab in patients with spinal muscular atrophy types 2 and 3: the phase 2 TOPAZ study. Neurology, 102(5), e209151. DOI: 10.1212/WNL.0000000000209151